%0 Generic
%A G., Gaitanis
%A P., Spyridonos
%A K., Patmanidis
%A V., Koulouras
%A G., Nakos
%A M., Tzaphlidou
%A I.D., Bassukas
%D 2012
%T Supplementary Material for: Treatment of Toxic Epidermal Necrolysis with the Combination of Infliximab and High-Dose Intravenous Immunoglobulin
%U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Treatment_of_Toxic_Epidermal_Necrolysis_with_the_Combination_of_Infliximab_and_High-Dose_Intravenous_Immunoglobulin/5123497
%R 10.6084/m9.figshare.5123497.v1
%2 https://karger.figshare.com/ndownloader/files/8709340
%2 https://karger.figshare.com/ndownloader/files/8709343
%2 https://karger.figshare.com/ndownloader/files/8709346
%K Toxic epidermal necrolysis
%K Infliximab
%K Immunoglobulin
%K Adverse drug reaction
%X Background: Therapeutic evidence for toxic epidermal necrolysis (TEN) is indicative for high-dose intravenous immunoglobulin yet inconclusive for corticosteroids. Objective: To describe the combination of corticosteroids, infliximab and a high-dose intravenous immunoglobulin course for TEN. Patients and Methods: In three patients (SCORTEN survival probabilities: 41.7%, 64.2%, 41.7%) disease control was evaluated by (a) employing quantitative image analysis to measure progression of skin detachment and (b) patients’ outcome (complete re-epithelization). Published cases of TEN treatments with infliximab were retrieved from PubMed. Results: Within 48 h skin disease progression was arrested in all patients. Two patients were discharged after 3 weeks without any sequels from skin or conjunctivae. One patient passed away on the ninth day, however with noticeably improved skin (mortality rate: 33% observed vs. 50% expected). A PubMed search retrieved five TEN patients treated successfully with infliximab. Conclusion: The described combination presents a feasible therapeutic alternative for TEN that warrants further evaluation.
%I Karger Publishers